Key Insights

Highlights

Success Rate

60% trial completion

Treatment Research

11 treatments under study, led by Thymoglobulin

Research Leaders

10 sponsors active, led by King's College London

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 80/100

Termination Rate

40.0%

2 terminated out of 5 trials

Success Rate

60.0%

-26.6% vs benchmark

Late-Stage Pipeline

40%

2 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed with results

Key Signals

60% success

Data Visualizations

Phase Distribution

5Total
Not Applicable (1)
Phase 2 (2)
Phase 4 (2)

Trial Status

Completed3
Terminated2

Trial Success Rate

60.0%

Benchmark: 86.6%

Based on 3 completed trials

Clinical Trials (5)

Showing 5 of 5 trials
NCT02498977Phase 4TerminatedPrimary

Liver Immunosuppression Free Trial

NCT02356939Not ApplicableTerminatedPrimary

Removable Intraductal Stenting in Duct-to-duct Biliary Reconstruction in Liver Transplantation

NCT00117689Phase 2Completed

Evaluation of Thymoglobulin Induction and Reduced Doses of Calcineurin Inhibitors on Liver Transplant Rejection

NCT00166556Phase 2CompletedPrimary

A Trial to Assess Campath-1H and Tacrolimus Followed by Immunosuppression Withdrawal in Liver Transplantation

NCT00178425Phase 4CompletedPrimary

PK of MMF in Cadaveric vs Living Donor Liver Transplant Recipients

Showing all 5 trials

Research Network

Common Treatments

  • Thymoglobulin1
  • Serial Blood Sampling As Described In Protocol1
  • Estimation Of Creatinine Clearance At Regular Intervals1
  • Tacrolimus1
  • Tacrolimus Cyclosporine Andor Mycophenolic Acid Mycophenolate Mofetil Or Azathioprine1

Active Sponsors

  • King's College London1
  • Immune Tolerance Network (ITN)1
  • Roche1
  • Genzyme, a Sanofi Company1
  • Mayo Clinic1

Top Investigators

Related Conditions

  • Rejection Transplant1
  • Liver Dysfunction1

Activity Timeline